Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.73 |
| ▸ | TP53 | P04637 | 6/20 | 0.73 |
| ▸ | PTGES | O14684 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523371 | 0.89 | MAPT (0.65) | MAPTTP53PTGESSMN1; SMN2AGPAT2 | |
| SCHEMBL4516675 | 0.87 | PTGES (0.87) | MAPTTP53PTGESSMN1; SMN2AGPAT2 | |
| SCHEMBL4514083 | 0.87 | MAPT (0.73) | MAPTTP53PTGESSMN1; SMN2AGPAT2 | |
| SCHEMBL4514679 | 0.83 | TP53 (1.00) | MAPTTP53PTGESSMN1; SMN2AGPAT2 | |
| SCHEMBL4498530 | 0.80 | PTGES (1.00) | MAPTTP53PTGESAGPAT2 | |
| SCHEMBL4508941 | 0.79 | PTGES (0.82) | MAPTTP53PTGESAGPAT2 | |
| SCHEMBL4499844 | 0.79 | PTGES (0.82) | MAPTTP53PTGESSMN1; SMN2AGPAT2 | |
| SCHEMBL4523694 | 0.78 | PTGES (0.81) | MAPTTP53PTGESAGPAT2THRB | |
| SCHEMBL4518282 | 0.77 | PTGES (1.00) | MAPTTP53PTGESAGPAT2 | |
| SCHEMBL4503199 | 0.76 | MAPT (0.62) | MAPTTP53AGPAT2THRBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | MAPT 270/4885TP53 2523/4885PTGES 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.